Suppr超能文献

一种能够催化破坏严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突三聚体的纳米抗体的鉴定。

Identification of a nanobody able to catalyze the destruction of the spike-trimer of SARS-CoV-2.

作者信息

Wang Kai, Cao Duanfang, Liu Lanlan, Fan Xiaoyi, Lin Yihuan, He Wenting, Zhai Yunze, Xu Pingyong, Yan Xiyun, Wang Haikun, Zhang Xinzheng, Yang Pengyuan

机构信息

Key Laboratory of Epigenetic Regulation and Intervention, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.

National Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, 100101, China.

出版信息

Front Med. 2025 May 3. doi: 10.1007/s11684-025-1128-4.

Abstract

Neutralizing antibodies have been designed to specifically target and bind to the receptor binding domain (RBD) of spike (S) protein to block severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus from attaching to angiotensin converting enzyme 2 (ACE2). This study reports a distinctive nanobody, designated as VHH21, that directly catalyzes the S-trimer into an irreversible transition state through postfusion conformational changes. Derived from camels immunized with multiple antigens, a set of nanobodies with high affinity for the S1 protein displays abilities to neutralize pseudovirion infections with a broad resistance to variants of concern of SARS-CoV-2, including SARS-CoV and BatRaTG13. Importantly, a super-resolution screening and analysis platform based on visual fluorescence probes was designed and applied to monitor single proteins and protein subunits. A spontaneously occurring dimeric form of VHH21 was obtained to rapidly destroy the S-trimer. Structural analysis via cryogenic electron microscopy revealed that VHH21 targets specific conserved epitopes on the S protein, distinct from the ACE2 binding site on the RBD, which destabilizes the fusion process. This research highlights the potential of VHH21 as an abzyme-like nanobody (nanoabzyme) possessing broad-spectrum binding capabilities and highly effective anti-viral properties and offers a promising strategy for combating coronavirus outbreaks.

摘要

中和抗体被设计用于特异性靶向并结合刺突(S)蛋白的受体结合域(RBD),以阻止严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒附着于血管紧张素转换酶2(ACE2)。本研究报告了一种独特的纳米抗体,命名为VHH21,它通过融合后构象变化直接催化S三聚体转变为不可逆的过渡状态。从用多种抗原免疫的骆驼中获得的一组对S1蛋白具有高亲和力的纳米抗体,显示出中和假病毒感染的能力,对包括SARS-CoV和BatRaTG13在内的SARS-CoV-2关注变体具有广泛抗性。重要的是,设计并应用了基于可视化荧光探针的超分辨率筛选和分析平台来监测单个蛋白质和蛋白质亚基。获得了一种自发形成的VHH21二聚体形式,可快速破坏S三聚体。通过低温电子显微镜进行的结构分析表明,VHH21靶向S蛋白上特定的保守表位,与RBD上的ACE2结合位点不同,这会破坏融合过程。本研究突出了VHH21作为一种具有广谱结合能力和高效抗病毒特性的类抗体纳米抗体(纳米酶)的潜力,并为对抗冠状病毒爆发提供了一种有前景的策略。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验